Seeking Alpha2h
Centessa: Shift In Focus With ORX750 Development Continues To Pay Off
The last time I wrote about Centessa Pharmaceuticals plc (NASDAQ:CNTA), it was in a Seeking Alpha article entitled “Centessa ...
ConsumerAffairs5h
FDA approves generic GLP-1 drug to treat type 2 diabetes
The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...
Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High
I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating ...
Medscape2d
FDA Approves Second Generic Daily GLP-1 Drug for T2D
The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...
The American Journal of Managed Care3d
FDA Approves First Generic Daily GLP-1 Injection for Type 2 Diabetes
The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...
Novo Nordisk new obesity therapy CagriSema outperforms semaglutide in Phase 3 trial
Novo Nordisk’s (NVO) next-gen weight loss therapy, CagriSema, caused up to ~23% of weight loss compared to ~16% of weight ...